Eton Q1 2021 Earnings Report
Key Takeaways
Eton Pharmaceuticals reported a record revenue of $11.9 million and its first profitable quarter with an operating income of $5.4 million. The company's success is attributed to three revenue-generating products and payments from the sale of neurology oral liquids products.
Achieved record revenue of $11.9 million in Q1 2021.
Reported operating income of $5.4 million, marking the first profitable quarter.
Launched Alaway Preservative Free with a $1.5 million milestone payment plus royalties.
Completed the sale of neurology oral liquid products, receiving $9.5 million in the first quarter and potential milestone payments up to $45 million plus royalties.
Eton
Eton
Forward Guidance
Eton Pharmaceuticals expects to have a number of additional products launched later this year as a result of the four upcoming PDUFA dates over the next three months. The company expects full year 2021 R&D expenses to be substantially below 2020 levels.